Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of two intravenous iron regimens combined with epoetin beta for chemotherapy-induced anemia
2009-011187-11Phase 3Active
- Sponsor
- ACROSS Group
- Start
- May 2009
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin beta and Iron in anemia of inflammation (AI) and chemotherapy-induced anaemia (CIA) (2 arms), sponsored by ACROSS Group. Primary endpoint: Hematologic response rate. Started May 2009; status: active.
02
Drugs
epoetin betaIron
03
Conditions
anemia of inflammation (AI)chemotherapy-induced anaemia (CIA)
Beyond the preview
Go deeper on 2009-011187-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011187-11.